1228553-72-7

Basic information

• Product Name: C₁₆H₂₂BrN₃O₃
• Synonyms: C₁₆H₂₂BrN₃O₃
• CAS NO: 1228553-72-7
• Molecular Weight: 384.273
• Mol File: 1228553-72-7.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 535.0±50.0 °C(Predicted)
• Density: 1.455±0.06 g/cm3(Predicted)
• CAS DataBase Reference: C₁₆H₂₂BrN₃O₃(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₆H₂₂BrN₃O₃(1228553-72-7)
• EPA Substance Registry System: C₁₆H₂₂BrN₃O₃(1228553-72-7)

Safety Data

• Hazardous Substances Data: 1228553-72-7(Hazardous Substances Data)

Upstream product

• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 1575-37-7 4-Bromo-benzene-1,2-diamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 147-85-3 L-proline 

Downstream Products

• 1208007-67-3 (S)-tert-butyl 2-(6-bromo-1H-benzo[d]imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1228969-01-4 tert-butyl (2S)-2-[5-(4-bromophenyl)-1H-benzimidazol-2-yl]pyrrolidine-1-carboxylate 
• 1208007-67-3 1,1-dimethylethyl (2S)-2-(5-bromo-1H-benzimidazol-2-yl)-1-pyrrolidinecarboxylate 
• 1256385-57-5 (S)-tert-butyl 2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-benzo[d]imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1275033-97-0 C₃₉H₄₇N₅O₅ 
• 1275033-98-1 C₃₉H₄₇N₅O₅ 
• 1275019-54-9 C₃₄H₄₁N₅O₅ 
• 1275034-58-6 C₂₄H₂₅N₅O 
• 1275019-58-3 C₃₂H₄₁N₅O₅ 
• 1419389-57-3 C₅₃H₆₈N₆O₆Si 
• 1419385-35-5 C₅₁H₆₀N₈O₇ 
• 1228969-01-4 (S)-tert-butyl 2-(6-(4-bromophenyl)-1H-benzo[d]imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1256385-57-5 (S)-tert-butyl 2-(6-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1Hbenzo[d]imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1228968-06-6 (1-{2-[6-(4-{2-[1-(2-methoxycarbonylamino-3-methylbutyryl)pyrrolidin-2-yl]-3Himidazol-4-ylethynyl}phenyl)-1H-benzoimidazol-2-yl]pyrrolidine-1-carbonyl}-2-methylpropyl)carbamic acid methyl ester 

Relevant articles and documents

HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS

A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF

The present invention belongs to the field of chemical pharmaceuticals, and specifically relates to compounds represented by formula I having a 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene structure and being able to inhibit hepatitis C virus activity, or a pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug of said compounds, a pharmaceutical composition containing said compounds, and an application of said compounds or composition in the preparation of a drug. The compounds of the present invention have a good HCV inhibitory effect.

SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS

Disclosed are spiro compounds of formula (I), or stereomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof. The compounds can be used to treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore disclosed are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions in the treatment of HCV infection or hepatitis C disease.